A microscale assay for the identification of TGF-β antagonists based on functional coupling of the heterodimeric TGF-β receptor to STAT6-driven promoter activation

Signal Transduction

Volumn 5, Issue 4, 2005, Pages 177-183

  Krause, Sebastian ^a,b   Friedrich, Karlheinz ^a,c  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF OLDENBURG   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cytokine receptors; Drug screening; Reporter cell line; TGF

Indexed keywords

INTERLEUKIN 4 RECEPTOR; LUCIFERASE; RECEPTOR BLOCKING AGENT; STAT6 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING ASSAY; BIOASSAY; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; GENE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; RECEPTOR BINDING; REPORTER GENE;

MURINAE;

EID: 24944456311     PISSN: 16154053     EISSN: None     Source Type: Journal    
DOI: 10.1002/sita.200400042     Document Type: Article

References (29)

1. Lawrence, D.A. (1996) Transforming growth factor-β: a general review. Eur. Cytokine Netw. 7: 363-374.
2. Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., Annunziata, N., Doetschman, T. (1992) Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693-699.
3. Grainger, D.J., Kemp, P.R., Metcalfe, J.C., Liu, A.C., Lawn, R.M., Williams, N.R., Grace, A.A., Schofield, P.M., Chauhan, A. (1995) The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nature Med. 1: 74-79.
4. Markowitz, S.D., Roberts, A.B. (1996) Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 7: 93-102.
5. Harada, M., Matsunaga, K., Oguchi, Y., Iijima, H., Ito, O., Tamada, K., Kimura, G., Nomoto, K. (1995) The involvement of transforming growth factor beta in the impaired anti-tumor T-cell response at the gut-associated lymphoid tissue (GALT). Cancer Res. 55: 6146-6151.
6. Barral-Netto, M., Barral, A., Brownell, C.E., Skeiky, Y.A., Ellingsworth, L.R., Twardzik, D.R., Reed, S.G. (1992) Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257: 545-548.
7. Miyazaki, Y., Araki, K., Vesin, C., Garcia, I., Kapanci, Y., Whitsett, J.A., Piguet, P.F., Vassalli, P. (1995) Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 96: 250-259.
8. Sehgal, I., Baley, P.A., Thompson, T.C. (1996) Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res. 56: 3359-3365.
9. Alevizopoulos, A., Mermod, N. (1997) Transforming growth factor-β: the breaking open of a black box. BioEssays 19: 581-591.
10. Massagué, J., Chen, Y.-G. (2000) Controlling TGF-β signaling. Genes Dev. 14: 627-644.
11. Huang, J.S., Wang, Y.H., Ling, T.Y., Chuang, S.S., Johnson, F.E., Huang, S.S. (2002) Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring. FASEB J. 16: 1269-1270.
12. Muraoka, R.S., Dumont, N., Ritter, C.A., Dugger, T.C., Brantley, D.M., Chen, J., Easterly, E., Roebuck, L.R., Ryan, S., Gotwals, P.J., Koteliansky, V., Arteaga, C.L. (2002) Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109: 1551-1559.
13. Yang, Y.A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J.J., MacGregor, J., Patel, S.C., Khozin, S., Liu, Z.Y., Green, J., Anver, M.R., Merlino, G., Wakefield, L.M. (2002) Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109: 1607-1615.
14. Vilchis-Landeros, M.M., Montiel, J.L., Mendoza, V., Mendoza-Hernandez, G., Lopez-Casillas, F. (2001) Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem. J. 355: 215-222.
15. Wrana, J.L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X.F., Massagué, J. (1992) TGF-β signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014.
16. Liu, X., Sun, Y., Constantinescu, S.N., Karam, E., Weinberg, R.A., Lodish, H.F. (1997) Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc. Natl. Acad. Sci. USA 94: 10669-10674.
17. Grotzinger, J. (2002) Molecular mechanisms of cytokine receptor activation. Biochem. Biophys. Acta. 1592: 215-223.
18. Krause, S., Würdemann, D., Wentzel, A., Christmann, A., Fehr, H., Kolmar, H., Friedrich, K. (2004) Bacteria displaying interleukin-4 mutants stimulate mammalian cells and reflect the biological activities of variant soluble cytokines. ChemBioChem. 5: 804-810.
19. Kammer, W., Lischke, A., Moriggl, R., Groner, B., Ziemiecki, A., Gurniak, C.B., Berg, L.J., Friedrich, K. (1996) Homodimerization of interleukin-4 receptor a chain can induce intracellular signaling. J. Biol. Chem. 271: 23643-23637.
20. Persson, U., Souchelnytskyi, S., Franzen, P., Miyazono, K., ten Dijke, P., Heldin, C.H. (1997) Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type MB receptor. J. Biol. Chem. 272: 21187-21194.
21. Lischke, A., Moriggl, R., Brändlein, S., Berchthold, S., Kammer, W., Sebald, W., Groner, B., Liu, X., Henninghausen, L., Friedrich, K. (1998) The interleukin-4 receptor activates STAT5 by a mechanism that relies upon common γ-chain. J. Biol. Chem. 273: 31222-31229.
22. Schmidt, W., Buschle, M., Zauner, W., Kirlappos, H., Mechtler, K., Trska, B., Birnstiel, M.L. (1997) Cell-free tumor antigen peptide-based cancer vaccines. Proc. Natl. Acad. Sci. USA 94: 3262-3267.
23. Friedrich, K., Kammer, W., Erhardt, I., Brändlein, S., Sebald, W., Moriggl, R. (1999) Activation of STAT5 by IL-4 relies on janus kinase function but not on receptor tyrosine phosphorylation, and can contribute to both cell proliferation and gene regulation. Int. Immunol. 11: 1283-1293.
24. Huang, S.S., Liu, Q., Johnson, F.E., Konish, Y., Huang, J.S. (1997) Transforming growth factor beta peptide antagonists and their conversion to partial agonists. J. Biol. Chem. 272: 27155-27159.
25. Gilboa, L., Wells, R.G., Lodish, H.F., Henis, Y.I. (1998) Oligomeric structure of type I and type II transforming growth factor-β receptors: homodimers form in the ER and persist at the plasma membrane. J. Cell. Biol. 140: 767-777.
26. Letourneur, O., Goetschy, J.-F., Horsiberger, M., Grütter, M.G. (1996) Ligand-induceddimerization of the extracellular domain of the TGF-β receptor type II. Biochem. Biophys. Res. Commun. 224: 709-716.
27. Kirsch, T., Sebald, W., Dreyer, M.K. (2000) Crystal structure of the BMP-2-BRIAectodomain complex. Nature Struct. Biol. 7: 492-496.
28. Zhu, H.J., Sizeland, A.M. (1999) Extracellular domain of the transforming growth factor-beta receptor negatively regulates ligand-independent receptor activation. J. Biol. Chem. 274: 29220-29227.
29. Seidel, H.M., Milocco, L.H., Lamb, P., Darnell, J.E. Jr., Stein, R.B., Rosen, J. (1995) Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc. Natl. Acad. Sci. USA 92: 3041-3045.